A process for the dimerization of ethylene to 1-butene, carried out with a catalytic composition comprising: at least one nickel precursor with an oxidation number of (+II), at least one phosphine ligand with formula PR.sub.1R.sub.2R.sub.3 in which the groups R.sub.1, R.sub.2 and R.sub.3 may be identical or different and which may or may not be bonded together, and at least one activating agent selected from the group formed by chlorinated and brominated hydrocarbylaluminium compounds, used alone or as a mixture, the composition having a molar ratio of the phosphine ligand to the nickel precursor in the range 5 to 30 and a molar ratio of the activating agent to the phosphine ligand greater than or equal to 1.

Catalytic processes employing rhodium complexes are disclosed, wherein the catalytic processes involve an initial step of activation of a CH bond present within a hydrocarbon substrate. In contrast to prior art techniques, the catalytic processes of the invention can be conducted at low temperatures, and the catalytic compounds are themselves highly recyclable. Also disclosed are the rhodium complexes themselves and processes of making them.

The present invention refers to processes for catalytic reversible alkene-nitrile interconversion through controllable HCN-free transfer hydrocyanation.

Markovnikov-selective palladium catalyst for carbonylation of alkynes is formed from a bisphosphite having formula (1): ##STR00001## The carbonylation catalyst is suited for the preparation of a branched heteroarene-keto product from an alkyne substrate, CO and heterocycle in high yields with low amounts of the linear product.

Methods for preparing the Bruton's Tyrosine Kinase (BTK) inhibitor compound 2-{3-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4]bipyridinyl-2-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided.

An o-aminoheteroaryl alkynyl-containing compound has a structure represented by formula (I), and the compound of formula (I) has advantages of a high FGFR and RET double target inhibitory activity and a relatively low KDR activity, and the compound of formula (I) exhibits a strong inhibitory activity in a human lung cancer cell line NCI-H1581 and a gastric cancer cell line SNU16 as well as an RET-dependent sensitive cell line BaF3-CCDC6-Ret and a mutant thereof. Pharmacokinetic data shows that the o-aminoheteroaryl alkynyl-containing compound has druggability, and exhibits significant relevant inhibition of the growth of related tumors in a long-term animal model of drug efficacy and results in favorable animal condition at effective doses.

##STR00001##

Disclosed herein are methods to rejuvenate a deactivated hydroformylation catalyst solution wherein the solution comprises rhodium, polydentate phosphine ligands, and polydentate phosphine ligand degradation products. In one embodiment, such methods comprise adding a peroxide to the deactivated hydroformylation catalyst solution.

The present disclosure provides methods for enantioselective synthesis of cyclic and acyclic -quaternary carboxylic acid derivatives via nickel-catalyzed allylic alkylation.

This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.

A compound represented by the structure of formula (I):

##STR00001##

The compound is useful as a ligand for ruthenium to form an organometallic complex. The complex may be immobilized on an oxidic support to form an active, heterogeneous catalyst for the hydrogenolysis of amides to form amines and optionally alcohols.